Manipal Health Enterprises Limited share price

NSE: MANIPALHOS · ISIN INE459N01021

Key numbers

Market cap
₹ 95,694 Cr
Current price
₹ 727.50
52-week high / low
₹ 815 / 625
Stock P/E
151.6
Book value
₹ 71.4
Dividend yield
0.00%
ROCE
10.8%
ROE
9.2%
Debt to equity
1.53
Sales growth (3 yrs)
-
Profit growth (3 yrs)
-
1-year return
-

About Manipal Health Enterprises Limited

Manipal Health Enterprises Limited operates hospitals in India. The company offers services, such as multi-specialty tertiary and quaternary care through its network of hospitals. Its services include accident and emergency care, cancer care, cardiology, organ transplants, obstetrics and gynaecology, neurology, nephrology, orthopaedics, proctology, rheumatology, and urology. The company also offers medical services, including robotic spine surgery, bariatric surgery, head and neck surgery, liver transplantation, dialysis, laparoscopic surgery, organ transplant, orthopaedic robotic surgery, spine care, and clinics for conditions like epilepsy, chronic pain, and diabetes. In addition, it offers home care, a woman's and childcare centre, an insurance helpdesk, and international patient services, diagnostic services, pharmacy sales, home healthcare, teleconsultations, e-pharmacy, and digital health solutions. Further, it delivers outpatient treatment, diagnostics, and advanced clinical care through its hospital network, and collaborates with foundations and NGOs to offer healharmathcare services to underserved populations. The company was formerly known as Manipal Health Enterprises…

Concall summary (2026-08-27)

AI summary of the earnings call transcript · tone: Positive · source document

Guidance & outlook

  • Our telehealth solutions completed over 17,000 virtual consultations, and our chatbot, including the MAI, what we call the Manipal AI -enabled digital health companion -- handled over 9,600 interactions during the quarter one of FY27.
  • Our Centres of Excellence, the six centres that we consider as our high -acuity specialties -- Cardiology, Cardiac Sciences actually, Oncology, Neurology, Gastroenterology, Orthopaedics, and Renal Sciences continue to be a key growth driver, their revenue contribution rising to about 65% in Q1 of FY27.

Growth & demand

  • First of all, we are pleased that our growth was driven by volumes -- more patients accessing our care during this quarter as well, as we believe that is a sustainable option for growth in care delivery.
  • Our inpatient volumes grew by about 39%, and OP volumes by 26% over Q1 of last year.

Margins & costs

  • Our network EBITDA was INR749 crores, a growth of over 26% over last year.
  • Our operating margin excluding Sahyadri was 25%, and at a network level that includes Sahyadri Hospitals, is at 24.2% for the quarter.

Capex & expansion

  • In other updates, we commissioned a brownfield capacity addition of 103 beds along with the newly installed linear accelerator and PET -CT at our Nashik hospital, increasing its overall licensed bed capacity to 307 beds.
  • As far as the capex for the current year is concerned, I think so current year, we will end up spending almost INR2,000 crores of capex because of the greenfields and brownfields that are coming up.

Balance sheet & cash

  • As far as leverage is concerned, the net debt to EBITDA is around 2.8x.
  • Once we repay this debt, which we will do in Q uarter 2, since the trigger has already been initiated post receiving the IPO funds, our net debt to EBITDA will go down to 0.9x at quarter 1 level.

Peers in Medical Care Facilities

Data for information only, not investment advice. Prices end of day.